Skip to main content
NCBI home page
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2026 Mar 8;20(3):e70164. doi: 10.1111/eip.70164

Duration of Untreated Eating Disorder and Prodrome in Young People: Characteristics and Relationship to Early Outcomes

Jessica McClelland 1,2, Amelia Austin 2, Michaela Flynn 2, Victoria A Mountford 2,3, Mima Simic 1,2, Ulrike Schmidt 1,2,✉
PMCID: PMC12968482  PMID: 41797321

ABSTRACT

Aims

Eating disorders (EDs) are serious illnesses and a better understanding of initial symptom phases could inform early intervention. This study aims to evaluate duration of untreated eating disorder (DUED) and duration/characteristics of the preceding prodrome period in young people diagnosed with an ED.

Methods

Fifty‐four young people (28 adolescents aged 13–17 and 26 emerging adults aged 18–25) with recent onset EDs (< 3 years) completed a retrospective onset interview and life chart. DUED, prodrome duration and prodrome characteristics (ED‐specific and more broad psychiatric symptoms) were compared according to developmental stage and diagnosis. The relationships between DUED and prodrome duration with early outcomes were evaluated.

Results

Emerging adults had a longer DUED than adolescents. This group also had a longer prodrome but only when broad psychiatric symptoms (i.e., not ED‐specific) were considered. Those with bulimia‐type EDs had a longer ED‐specific and broad psychiatric prodrome compared to those with anorexia‐type EDs. There were no significant developmental stage or diagnosis‐related differences in symptom severity during prodrome. In those who were underweight at presentation to services, a shorter broad prodrome duration was associated with greater weight gain after 3 months of treatment.

Conclusions

When both ED and broad psychiatric symptoms are considered, DUED and prodromal symptoms of EDs differ according to developmental stage and diagnosis. Duration of prodrome may also impact early outcomes but further research is needed.

Keywords: anorexia nervosa, bulimia nervosa, duration of untreated eating disorder, eating disorders, prodrome

1. Introduction

Eating disorders (EDs) are characterised by disturbed eating and weight/shape concerns. They affect approximately 8% of women and 2% of men in their lifetime (Galmiche et al. 2019). Around 75% of people who develop an ED do so between the ages of 14 and 25 (Solmi et al. 2022), thus EDs typically arise during adolescence or emerging adulthood, a crucial stage of biopsychosocial development. EDs are associated with significant physical and psychosocial burden, psychiatric comorbidity, disability and mortality (Schmidt et al. 2025). EDs are conceptualised as developing from early risk and prodromal states into full‐threshold illness. Clinical staging models describe progression from early/mild illness to severe and enduring forms, with stage informing prognosis and treatment intensity (Treasure et al. 2015; Hyam et al. unpublished manuscript).

Prompt intervention is associated with improved chances for recovery (Ambwani et al. 2020; Treasure et al. 2015), therefore, services that treat early stage EDs are crucial. Such early intervention services have begun to emerge in EDs (Schmidt et al. 2016) and have reported superior clinical outcomes compared to usual treatment (Austin, Flynn, Shearer, et al. 2022; Fukutomi et al. 2020; McClelland et al. 2018; Richards et al. 2022). These services aim to reduce the duration of untreated ED (DUED), defined as the duration of time between illness onset and specialist ED treatment. Our review found that average DUED ranged from 2.5 to 6 years across the most common EDs and differed according to diagnosis (Austin et al. 2020). Moreover, DUED appears to be associated with age, meaning that younger individuals have a shorter DUED (Austin et al. 2020; Chew et al. 2021). Specifically, Weigel et al. (2014) found that compared to adolescents (under 18 years), emerging adults (aged 18–25 years) had a longer DUED of around 6 months. Importantly, predictors of outcome in early intervention have started to be explored, including baseline characteristics and early change trajectories (Allen et al. 2025; Austin, Flynn, Richards, et al. 2021).

Along with improved understanding of DUED, there is a need to know more about the earliest illness phase of EDs. This is known as ‘prodrome’ and relates to the period immediately preceding ED onset (Le Grange and Loeb 2007; Treasure et al. 2015). This period has been extensively researched in other psychiatric disorders, especially psychosis (Woodberry et al. 2016). Studies report on the duration, characteristics and predictive ability of prodromal psychosis (Barajas et al. 2019; Renwick et al. 2015; Valmaggia et al. 2015), leading to the development of robust prodrome assessment methods (e.g., Singh et al. 2005) and clinical services devoted to these prodromal ‘high‐risk’ stages of illness (Fusar‐Poli et al. 2013, 2016).

In comparison, little research exists on prodrome stages of ED, in part due to difficulties defining this (Treasure et al. 2015). As outlined by Stice et al. (2010) a prodrome is one or more symptoms which indicates and predates future ED onset. Raffi et al. (2000) assessed a range of symptoms 6 months prior to bulimia nervosa (BN) onset, finding that affective symptoms and low self‐esteem were the most common prodrome symptoms. In our evaluation of an early intervention ED service an average prodrome duration (including ED symptoms only) of 23.2 months was reported (Brown et al. 2018). Interestingly Del Barrio et al. (2022) found that young people with EDs presented more frequently to health services during ED prodrome, in relation to digestive, psychological, gynaecological and weight‐loss symptoms. More recently, compensatory weight‐control behaviours, lower weight status and the over‐evaluation of weight/shape were found to be the first prodromal symptoms of anorexia nervosa (AN). The same group identified prodromal binge eating and additional cognitive symptoms (e.g., feeling fat, fear of weight gain) to be associated with the onset of BN and BED (Yamamiya et al. 2023; Stice et al. 2021). Our latest study in young adults found that neither DUED nor duration of ED prodrome predicted clinical outcomes (e.g., weight, ED psychopathology and behaviours; Austin, Flynn, Richards, et al. 2025).

No standardised method of measuring prodromes in EDs exists. Given the high rates of psychiatric comorbidity in EDs (e.g., mood disorders ~54%, anxiety disorders ~62%; Hambleton et al. 2022) there is some ambiguity as to whether the prodrome is limited to the emergence of ED symptoms (ED‐specific prodrome) or includes broader psychiatric disorder‐related symptoms (total prodrome) (McClelland et al. 2020). This study aimed to gain a better understanding of DUED and the prodrome (both ED‐specific and total) in EDs. We compare the characteristics of DUED and prodromes between different developmental stages and diagnostic groups. We also explore the relationship between DUED and prodrome to early treatment outcomes. We hypothesised that:

  1. DUED and prodrome duration would be shorter in adolescents compared to emerging adults. Prodrome symptoms were expected to be less severe in adolescents compared to emerging adults.

  2. Shorter DUED and prodrome would be associated with better early treatment outcomes (e.g., improved psychopathology, weight gain).

2. Methods

Ethical approval for the project was given by the National Research Ethics Service Committee London (ref: 16/LO/1882).

2.1. Participants

Adolescents (aged 13–17) and emerging adults (aged 18–25) recently diagnosed with an ED as defined by the DSM‐5 (American Psychiatric Association 2013) were recruited (between 2017 and 2019) from the child and adolescent and adult ED services at the same hospital in South London, UK. Consent from the participant and/or a parent was obtained before enrolment in the study. Exclusion criteria were: age below/above 13–25 years, an ED duration > 3 years, no primary ED diagnosis, a severe physical/mental comorbidity requiring priority treatment, a severe learning disability or immediate inpatient admission.

2.2. Measures

Onset interview: An extended version of the onset interview and life chart we used previously was administered (Brown et al. 2018). This assessed the previous 5 years (rather than 3 years), in an attempt to capture both DUED and prodrome. Central to the interview is the life chart, which uses ‘anchor points’ (e.g., birthdays, starting university, etc.) to help orientate the young person to the timing of symptoms. The interview and life chart were completed by three of the authors, with extensive experience in these measures (via their involvement in FREED; authors J.M., A.A., M.F.). The completion of the interview and life chart was facilitated by researchers using an adapted version (including symptom onset, severity and progression) of the Eating Disorder Diagnostic Scale (EDDS) to assess the severity, frequency and duration of ED‐related psychological, behavioural and physical symptoms (Stice et al. 2000).

The broad psychiatric symptom screener, a novel interview schedule, captured the timing, duration and severity of other psychiatric disorder‐related symptoms/diagnoses. Information gathered from the adapted EDDS and the broad psychiatric symptom screener was used to collaboratively complete the 5‐year retrospective life chart with the young person in relation to the severity and impact of symptoms. After the interview, prodrome characteristics (onset, severity, distress, number of comorbid diagnoses), duration of ED‐specific prodrome, duration of total prodrome and DUED were calculated (see Box 1 for details). Further information on all materials can be found in the Supporting Information Material.

BOX 1. Definitions of outcomes measured by the onset interview and life chart.

Duration of untreated eating disorder (DUED): The length of time between ED onset (as defined by DSM‐5 criteria) and the start of specialist, evidence‐based treatment.

ED‐specific prodrome onset: Date of first ED‐specific symptom (e.g. feeling fat, fear weight gain, influence weight/shape, excessive exercise, binge, purge or weight loss) at any rating greater than zero.

Total prodrome onset: Date of first psychiatric symptom, ED‐specific or otherwise (e.g., related to depression, anxiety, obsessive compulsive disorder [OCD], body dysmorphic disorder [BDD], substance abuse disorder [SUD]) at any rating greater than zero.

ED onset: Date symptoms met ED diagnosis as defined by DSM‐5.

Duration of ED‐specific prodrome: The length of time (months) between date of first ED‐specific symptom (e.g., feeling fat, fear weight gain, influence weight/shape, excessive exercise, binge, purge or weight loss) at any rating greater than zero and date of ED onset (as defined by DSM‐5 criteria).

Duration of total prodrome: The length of time (months) between the date of first psychiatric symptom, ED‐specific OR otherwise (e.g., related to depression, anxiety, OCD, BDD, SUD), at any rating greater than zero and the date of ED onset (as defined by DSM‐5 criteria).

Symptom severity during prodrome: Average rating across symptoms (ED psychological: 0 ‘not at all’ to 6 ‘extremely’; ED behavioural: 0 to 7 days/14 times per week; other psychiatric disorder related: 0 ‘not at all’ to 3 ‘nearly every day’) during prodrome.

Number of other psychiatric disorder‐related diagnoses during prodrome: Total number of other psychiatric‐disorder related diagnoses (e.g., depression, anxiety, OCD, BDD, SUD) during prodrome.

Distress related to and impact of difficulties during prodrome: Ratings of level of distress/impact (0 ‘no distress/impact’ to 10 ‘significant distress/impact’) of the ED‐specific and other psychiatric disorder‐related symptoms during prodrome.

Eating Disorder Examination Questionnaire (EDE‐Q)—Version 6. The EDE‐Q evaluated ED behaviours and cognitions in the past 28 days (Fairburn and Beglin 2008). High scores indicate more severe symptoms, with a proposed clinical cut‐off score of ≥ 2.8 (Mond et al. 2008).

Demographic and clinical characteristics (e.g., age, ethnicity) were collected via research interview and from clinical records. Service information including date of initial clinical assessment, and early treatment outcomes (weight and EDE‐Q score) at 3 and 6 months after treatment start were extracted from clinical records.

2.3. Procedures

In the child and adolescent ED service, clinicians introduced the study to young people and their families early in treatment, whilst in the adult ED service, participants were those that took part in a larger study of a novel early intervention service (FREED‐Up; Allen et al. 2020; Flynn et al. 2021). Study information was provided, and consent was obtained before administration of the onset interview.

2.4. Analyses

Statistical analyses were performed using IBM SPSS software (Version 25). Normality and other relevant assumptions of variables were assessed (via Kolmogorov–Smirnov and Levene's test statistics) and as most data were non‐normally distributed, non‐parametric tests and statistics were used. All tests were two tailed and with α = 0.05 significance.

Mann–Whitney and Pearson's chi‐squared tests were used to compare demographic and clinical characteristics. The effect sizes for these are r and Cramer's V respectively. Their interpretation of magnitude is 0.1–0.3 small, 0.3–0.5 medium, and > 0.5 large.

Kaplan–Meier survival analysis was used to compare differences (defined by hazard functions) in DUED, duration of ED‐specific and total prodrome according to developmental stage and diagnosis. The hazard function represents the probability of remaining in the dependent variable (e.g., DUED, prodrome) at any given time. Diagnostic subgroups were broadly split into anorexia nervosa (AN; including atypical AN), and BN or binge eating disorder (BED).

3. Results

3.1. Sample Characteristics

A total of 54 young people (predominantly female, 94%), 28 adolescents and 26 emerging adults, participated in the study and were included in analyses. Table 1 presents demographic and baseline clinical information for the entire sample and for subgroups. Comparing the adolescent and emerging adult groups, there were significant differences in ethnicity (higher proportion of white young adults; χ 2[2, n = 54] = 9.59, p = 0.01. V = 0.42) and, for those with AN, BMI (lower in adolescents; U = 62.50, p = 0.01, r = 0.43). There were no other significant differences between the developmental stage groups across demographic and clinical characteristics at the time of research interview. However, there was a significant difference in the duration of time between initial clinical assessment and the time of research interview (U = 90.50, p < 0.001, r = 0.66), with a larger gap in time (in months) for adolescents (Mdn = 3, Min = 0, Max = 25) compared to emerging adults (Mdn = 0, Min = 0, Max = 3). As expected, diagnostic comparison (i.e., AN vs. BN/BED) showed significant differences in weight, indicated by BMI (U = 57, p < 0.001, r = 0.63) and percentage weight for height (U = 9, p < 0.001, r = 0.50) at clinical assessment. There were no other significant differences between diagnostic groups.

TABLE 1.

Demographic information at clinical assessment.

All (n = 54) Adolescents (n = 28) Emerging adults (n = 26) All AN/AAN (n = 32) All BN/BED (n = 16) Other EDs (n = 6)
Age 17 (13, 26) 15 (13, 17) 19 (17, 26) 17 (13, 24) 16 (14, 26)
Gender Female (n = 51) Female (n = 28) Female (n = 23) Female (n = 30) Female (n = 16) Female (n = 5)
Male (n = 3) Male (n = 0) Male (n = 3) Male (n = 2) Male (n = 0) Male (n = 1)
Ethnicity White (n = 38) White (n = 17) White (n = 21) White (n = 24) White (n = 11) White (n = 3)
Asian (n = 3) Asian (n = 0) Asian (n = 3) Asian (n = 2) Asian (n = 1) Asian (n = 0)
Other (n = 13) Other (n = 11) Other (n = 2) Other (n = 6) Other (n = 4) Other (n = 3)
ED diagnosis AN (n = 32) AN (n = 17) AN (n = 15) n/a n/a ARFID (n = 2)
BN/BED (n = 16) BN/BED (n = 8) BN/BED (n = 8)
OSFED (n = 4) OSFED (n = 1) OSFED (n = 3) OSFED (n = 4)
ARFID (n = 2) ARFID (n = 2)
BMI
AN/AAN 17.90 (14.38, 25.30) 17.50 (14.38, 25.30) 18.70 (14.70, 25.00) 17.90 (14.38, 25.30) n/a
BN/BED 23.00 (18.40, 30.90) 22.35 (18.40, 30.90) 23.00 (18.90, 24.70) n/a 23.00 (18.40, 30.90)
Other EDs 20.75 (17.67, 24.50) 18.79 (17.67, 24.50) 21.20 (20.30, 23.10) n/a n/a 18.79 (17.76, 24.50)
% W4H
AN/AAN n/a 84.40 (17.32, 133.06) n/a 84.40 (17.32, 133.06) n/a
BN/BED

119.73 (93.80, 146.00)

 n/a 113.76 (93.80, 146) 92.31 (84.26, 117)
Other EDs 92.31 (84.26, 117.00) n/a n/a
Open in a new tab

Note: Median and range reported.

Abbreviations: %W4H, percentage weight for height; AN, anorexia nervosa; BED, binge eating disorder; BN, bulimia nervosa; ED, eating disorder.

3.2. Duration of Untreated Eating Disorder

As represented in Figure 1 there was a trend towards a significant difference in the hazard functions of DUED (χ 2[1, n = 51] = 3.01, p = 0.08) between adolescents (Mdn = 6 months) and emerging adults (Mdn = 15 months). There were no significant differences (χ 2[1, n = 45] = 0.44, p = 0.51) in the hazard functions of DUED between those with AN (Mdn = 7 months) and those with BN/BED (Mdn = 7 months).

FIGURE 1.

FIGURE 1

Open in a new tab

Duration of untreated eating disorder (DUED) according to developmental stage.

3.3. Duration of Eating Disorder Specific Prodrome

There was no significant difference (χ 2[1, n = 54] = 1.58, p = 0.21) in the hazard functions between the two developmental groups (adolescent Mdn = 36 months; emerging adults Mdn = 40 months). However, there was a significant difference (χ 2[1, n = 48] = 8.92, p < 0.01) in the hazard functions between those with AN (Mdn = 35 months) versus those with BN/BED (Mdn = 79 months; see Figure 2).

FIGURE 2.

FIGURE 2

Open in a new tab

Duration of eating disorder specific prodrome according to diagnosis.

3.4. Duration of Total Prodrome

As demonstrated in Figure 3, there was a significant difference (χ 2[1, n = 54] = 6.02, p = 0.01) in the hazard functions between adolescents (Mdn = 45 months) and emerging adults (Mdn = 72 months) and between those with AN (Mdn = 45 months) versus those with BN/BED (Mdn = 96 months; χ 2(1, n = 48) = 7.83, p < 0.01; see Figure 4).

FIGURE 3.

FIGURE 3

Open in a new tab

Duration of total prodrome according to developmental stage.

FIGURE 4.

FIGURE 4

Open in a new tab

Duration of total prodrome according to diagnosis.

3.5. Prodrome Characteristics

Prodrome characteristics are presented in Table 2 for the entire sample and for age/diagnosis subgroups. Adolescents had a significantly earlier age of ED‐specific prodrome onset (U = 196.00, p < 0.01, r = 0.40) and total prodromal onset (U = 219.50, p = 0.03, r = 0.30) compared to emerging adults. There were no other significant differences between subgroups for any other prodrome characteristics, however there was a trend for individuals with BN/BED to have an earlier age of ED‐specific prodrome onset (U = 173, p = 0.07, r = 0.26) and increased distress during the prodrome (U = 93, p = 0.07, r = 0.31) compared to those with AN.

TABLE 2.

Characteristics of prodrome period. Median and range reported.

Developmental stage Diagnosis
All (n = 54) Adolescents (n = 28) Emerging adults (n = 26) p AN/AAN (n = 32) BN and BED (n = 16) p
Age of ED prodromal onset (years) 12 (3, 23) 11 (3, 17) 13.50 (3, 23) 0.01 12 (8, 19) 9.50 (3, 21) 0.07
Age of total prodrome onset (years) 12 (2, 23) 12 (2, 16) 15.50 (4, 23) 0.03 12 (4, 23) 12 (2, 23) 0.98
ED psychological symptom severity (0–6) 4 (2, 5.7) 4 (2, 5.7) 4 (2.2, 5.75) 0.81 4 (2, 5.7) 4.1 (2.1, 5.7) 0.15
ED binge/purge symptom severity (0–14) 3.5 (1, 14) 3 (1, 7.5) 4 (1.3, 14) 0.15 3 (1, 14) 4 (1, 5.7) 0.48
ED fasting/restriction symptom severity (0–7) 5.25 (1, 7) 5.25 (1, 7) 6 (2, 7) 0.14 5.5 (1, 7) 5 (2, 7) 0.93
Number of other psychiatric disorder‐related diagnoses 2 (0, 7) 2 (0, 6) 2 (0, 7) 0.80 2 (0, 7) 1 (0, 4) 0.26
Severity of broad psychiatric disorder‐related symptoms (0–3) 2.2 (1, 3) 2 (1.67, 3) 2.4 (1, 3) 0.32 2 (1, 3) 2.4 (1.7, 3) 0.10
Distress from difficulties (0–10) 8 (0, 10) 8 (0, 10) 8 (2, 10) 0.58 7 (0, 10) 8.5 (3, 10) 0.07
Impact of difficulties (0–10) 6 (0, 10) 6 (2, 10) 7 (0, 10) 0.23 5 (0, 10) 7 (4, 10) 0.50
Open in a new tab

Abbreviations: AN, anorexia nervosa; BED, binge eating disorder; BN, bulimia nervosa; ED, eating disorder.

3.6. Relationship to Early Outcomes

There was no significant relationship between DUED or prodrome (both ED‐specific or total) with ED psychopathology at 3 or 6 months after starting treatment (n = 22). In those who were underweight (BMI ≤ 18.5 kg/m2) at initial clinical assessment there was no significant relationship between DUED and weight gain at 3 months (n = 21) or 6 months (n = 16) after starting treatment. However, there was a significant correlation between duration of total prodrome (r s = −0.52, p = 0.02, n = 21) with weight gain 3 months after starting treatment (i.e., shorter prodrome related to greater weight gain). At 6 months after starting treatment, there was no significant relationship between either ED‐specific or total prodrome duration and weight gain (n = 16). Of note, participants were typically still in early stages of treatment at the time of analyses, therefore data were sparse at the 3‐ and 6‐month time points.

4. Discussion

This study explored characteristics of early illness stages of EDs in young people according to developmental stage and diagnosis. Our first hypothesis, that DUED would be shorter in adolescents compared to emerging adults was supported, which fits with previous evidence (Austin et al. 2020; Weigel et al. 2014). This finding may be influenced by a number of factors. The differing demands of developmental stages (e.g., increased independence, transitions and responsibilities in young adults), related differences in help‐seeking behaviours (Copeland et al. 2015; Potterton et al. 2020; Nicula et al. 2022), i.e., increased parental input in accessing support and the mandated access and waiting times for adolescents compared to adults (i.e., treatment must start within 28 days [NHS England 2015, 2019]). Surprisingly, no diagnostic related differences in DUED were found, unlike our review which indicated that internationally DUED is longest in non‐underweight EDs (e.g., ~67 months in BED, ~53 months in BN and ~30 months in AN; Austin et al. 2020). This could be explained by our small, uneven sample sizes across diagnostic categories.

Our second hypothesis, that prodrome duration would be shorter and symptoms less severe in adolescents compared to emerging adults, was partially supported. While there was no significant difference in the duration of ED‐specific prodrome, when broad psychiatric disorder‐related symptoms were considered, adolescents had a shorter total prodrome compared to emerging adults. This suggests emerging adults may have a longer period of broad psychiatric symptoms prior to ED onset, which is important to consider when designing developmentally tailored prevention and early intervention strategies. In terms of symptom severity, whilst emerging adults described some heightened severity during the prodrome compared to adolescents (which is in line with previous findings, e.g., Fisher 2003; Hudson et al. 2007; Swanson et al. 2011), these differences were not significant.

Comparison of the duration and severity of prodrome by diagnosis (across all ages) revealed that those with BN/BED had a longer duration of ED‐specific and total prodrome and greater levels of distress during prodrome compared to those with AN, although this finding is limited by uneven sample sizes. These are in line with our previous findings of longer DUED in BN/BED (Austin et al. 2020) and could be explained by weight stigma, the tendency for EDs in non‐underweight individuals to often go unnoticed and their severity typically dismissed. Raffi et al. (2000) did not make any comparisons in relation to prodromal EDs, our findings are consistent with their reports of affective symptomatology during prodromal stages of BN.

Our third hypothesis was also partly supported, with shorter total prodrome associated with increased weight gain 3 months after starting treatment. This is similar to our findings elsewhere (Austin, Flynn, Shearer, et al. 2022; McClelland et al. 2018), and highlights the impact of early intervention, with consideration of broad psychiatric symptoms, on quick initial weight restoration. We did not find a relationship between prodrome duration and any other early outcomes, possibly in part due to our small sample size at these follow up time points.

4.1. Strengths and Limitations

To our knowledge, this is the first study to thoroughly and broadly investigate how early stages of EDs may differ in terms of duration and severity according to developmental stage and diagnoses. However, our methodology had some limitations. Firstly, the normalisation of diet culture is likely to have impacted the accuracy of historical accounts of ED symptoms. Relatedly, the retrospective nature of this study will have led to recall errors and biases, limiting validity and reliability. The simple Likert scales used to assess symptom severity may have impeded the ability to detect changes over time. Moreover, whilst the interview was designed to capture a broad range of symptoms, there were several important omissions, including symptoms of other developmentally relevant disorders (e.g., ARFID, ADHD) and other possible prodromal features (e.g., early childhood eating difficulties, low self‐esteem; Del Barrio et al. 2022; McClelland et al. 2020). Finally, several findings were nearing significance, indicating that this study is likely underpowered. The small, predominantly female sample in this study limits the reliability and generalisability of the current findings.

4.2. Clinical/Policy Implications and Future Research Directions

The clinical differences we found between developmental groups (i.e., DUED and duration of total prodrome) supports recent calls for age and stage appropriate access to care for young people with AN (Herpertz‐Dahlmann et al. 2021). Given our findings that those with BN/BED have an extended prodrome, and a trend for increased distress, this call to arms needs to include all ED diagnostic categories, not just those of low weight. Specifically worrisome is the lengthy nature of the DUED and total prodrome for emerging adults compared to adolescents. As mentioned previously, this may be due to different patterns in help seeking between developmental groups. Interventions that aim to promote help seeking targeted to emerging adults are needed and are currently being developed (Grycuk et al. 2025). The differences in durations between developmental groups may also be impacted by unequal service provision. Internationally, services/care pathways for EDs are often split between child/adolescent services and adult services, even though the onset of these illnesses straddles adolescence and emerging adulthood (Treasure, Oyeleye, et al. 2021). This parallel service structure results in disparate care provision depending on arbitrary age cut‐offs. Possible solutions include establishing ED services which span the age range and the introduction of similar access time targets for all. Finally, clinical applications of improved prodrome measurement in EDs include better identification of ultra‐high‐risk individuals for early intervention and increased measurement accuracy of ED symptom duration. Future studies should aim to improve the interview process in ways previously mentioned before replicating. Following such research, the refinement of the lengthy interview into a simple screening tool would be useful for both research and clinical purposes, as has been seen in other disorders (Register‐Brown and Hong 2014; Van Meter et al. 2016).

4.3. Conclusions

Emerging adults had a longer DUED than adolescents, as well as a longer prodrome when broad psychiatric symptoms were considered. Those with BN/BED had a longer duration of both ED‐specific and broad prodrome compared to those with AN. Shorter prodrome duration of broad psychiatric symptoms was associated with early weight gain in treatment, highlighting the importance of broad early identification and intervention. These novel findings require replication. Future work must refine the assessment tools and evaluate the clinical implications of an improved understanding of DUED and ED prodromes. Such research could inform early detection and intervention strategies, for example by tailoring these to the unique needs of emerging adults and BN/BED presentations, ultimately interrupting the course of EDs becoming treatment resistant and life‐threatening for many young people.

Funding

This work was supported by the Economic and Social Research Council (MR/W002418/1), Arts and Humanities Research Council (MR/W002418/1), Medical Research Council (MR/W002418/1) and National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC).

Supporting information

Data S1: eip70164‐sup‐0001‐Supinfo.docx.

EIP-20-0-s001.docx (15.1KB, docx)

Acknowledgements

Ulrike Schmidt is part‐funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). The views expressed herein are those of the authors and not necessarily those of the National Health Service (NHS), NIHR or Department of Health and Social Care. United States is also supported by the Medical Research Council/Arts and Humanities Research Council/Economic and Social Research Council Adolescence, Mental Health and the Developing Mind initiative as part of the EDIFY programme (grant number MR/W002418/1).

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

  1. Allen, K. , Austin A., Flynn M., et al. 2025. “Predictors of Treatment Outcome in an Early Intervention Eating Disorder Sample.” International Journal of Eating Disorders. 10.1002/eat.24593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allen, K. , Mountford V., Brown A., et al. 2020. “First Episode Rapid Early Intervention for Eating Disorders (FREED): From Research to Routine Clinical Practice.” Early Intervention in Psychiatry 14, no. 5: 625–630. 10.1111/eip.12941. [DOI] [PubMed] [Google Scholar]
  3. Ambwani, S. , Cardi V., Albano G., et al. 2020. “A Multicenter Audit of Outpatient Care for Adult Anorexia Nervosa: Symptom Trajectory, Service Use, and Evidence in Support of “Early Stage” Versus “Severe and Enduring” Classification.” International Journal of Eating Disorders 53, no. 8: 1337–1348. 10.1002/eat.23246. [DOI] [PubMed] [Google Scholar]
  4. American Psychiatric Association . 2013. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington. [Google Scholar]
  5. Austin, A. , Flynn M., Richards K., et al. 2020. “Duration of Untreated Eating Disorder and Relationship to Symptoms: A Systematic Review of the Literature.” European Eating Disorders Review 29: 329–345. 10.1002/erv.2745. [DOI] [PubMed] [Google Scholar]
  6. Austin, A. , Flynn M., Richards K., et al. 2025. “The Relationship Between Duration of Untreated Symptoms and Clinical Outcomes in First Episode Eating Disorders.” Psychiatry Research Communications 5, no. 2: 100217. 10.1016/j.psycom.2025.100217. [DOI] [Google Scholar]
  7. Austin, A. , Flynn M., Richards K. L., et al. 2021. “Early Weight Gain Trajectories in First Episode Anorexia: Predictors of Outcome for Emerging Adults in Outpatient Treatment.” Journal of Eating Disorders 9: 112. 10.1186/s40337-021-00448-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Austin, A. , Flynn M., Shearer J., et al. 2022. “The First Episode Rapid Early Intervention for Eating Disorders‐Upscaled Study: Clinical Outcomes.” Early Intervention in Psychiatry 16: 97–105. 10.1111/eip.13139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Barajas, A. , Pelaez T., Gonzalez O., et al. 2019. “Predictive Capacity of Prodromal Symptoms in First‐Episode Psychosis of Recent Onset.” Early Intervention in Psychiatry 13, no. 3: 414–424. 10.1111/eip.12498. [DOI] [PubMed] [Google Scholar]
  10. Brown, A. , McClelland J., Boysen E., Mountford V., Glennon D., and Schmidt U.. 2018. “The FREED Project (First Episode and Rapid Early Intervention in Eating Disorders): Service Model, Feasibility and Acceptability.” Early Intervention in Psychiatry 12, no. 2: 250–257. 10.1111/eip.12382. [DOI] [PubMed] [Google Scholar]
  11. Chew, C. S. E. , Kelly S., Baeg A., Oh J. Y., Rajasegaran K., and Davis C.. 2021. “First Presentation of Restrictive Early Onset Eating Disorders in Asian Children.” International Journal of Eating Disorders 54, no. 1: 81–87. 10.1002/eat.23274. [DOI] [PubMed] [Google Scholar]
  12. Copeland, W. E. , Shanahan L., Davis M., Burns B. J., Angold A., and Costello E. J.. 2015. “Increase in Untreated Cases of Psychiatric Disorders During the Transition to Adulthood.” Psychiatric Services 66, no. 4: 397–403. 10.1176/appi.ps.201300541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Del Barrio, A. G. , Ruiz Guerrero F., Benito Gonzalez P., et al. 2022. “A Retrospective Investigation of the Prodromal Stages of Eating Disorders and Use of Health Services in Young Patients the Year Prior to the Diagnosis.” Early Intervention in Psychiatry 16: 162–167. 10.1111/eip.13142. [DOI] [PubMed] [Google Scholar]
  14. Fairburn, C. , and Beglin S.. 2008. “Eating Disorder Examination Questionnaire (EDE‐Q 6.0).” In Cognitive Behavioural Therapy and Eating Disorders, edited by Fairburn C.. Guilford Press. [Google Scholar]
  15. Fisher, M. 2003. “The Course and Outcome of Eating Disorders in Adults and in Adolescents: A Review.” Adolescent Medicine Clinics 14, no. 1: 149–158. [PubMed] [Google Scholar]
  16. Flynn, M. , Austin A., Lang K., et al. 2021. “Assessing the Impact of First Episode Rapid Early Intervention for Eating Disorders (FREED) on Duration of Untreated Eating Disorder: A Multi‐Centre Quasi‐Experimental Study.” European Eating Disorders Review 29: 458–471. 10.1002/erv.2797. [DOI] [PubMed] [Google Scholar]
  17. Fukutomi, A. , Austin A., McClelland J., et al. 2020. “First Episode Rapid Early Intervention for Eating Disorders (FREED): A Two‐Year Follow‐Up.” Early Intervention in Psychiatry 14, no. 1: 137–141. 10.1111/eip.12881. [DOI] [PubMed] [Google Scholar]
  18. Fusar‐Poli, P. , Byrne M., Badger S., Valmaggia L. R., and McGuire P. K.. 2013. “Outreach and Support in South London (OASIS), 2001‐2011: Ten Years of Early Diagnosis and Treatment for Young Individuals at High Clinical Risk for Psychosis.” European Psychiatry 28, no. 5: 315–326. 10.1016/j.eurpsy.2012.08.002. [DOI] [PubMed] [Google Scholar]
  19. Fusar‐Poli, P. , Diaz‐Caneja C. M., Patel R., et al. 2016. “Services for People at High Risk Improve Outcomes in Patients With First Episode Psychosis.” Acta Psychiatrica Scandinavica 133, no. 1: 76–85. 10.1111/acps.12480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Galmiche, M. , Déchelotte P., Lambert G., and Tavolacci M. P.. 2019. “Prevalence of Eating Disorders Over the 2000–2018 Period: A Systematic Literature Review.” American Journal of Clinical Nutrition 109, no. 5: 1402–1413. 10.1093/ajcn/nqy342. [DOI] [PubMed] [Google Scholar]
  21. Grycuk, L. , Monssen D., Davies M. R., et al. 2025. “Shortening Duration of Untreated Illness in Young People With First Episode Eating Disorders: Protocol of a Randomised Controlled Feasibility Trial of a Smartphone Friendly Multi‐Modal Decision‐Making Tool (FREED‐M) to Improve Help‐Seeking.” Pilot and Feasibility Studies 11: 14. 10.1186/s40814-024-01585-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hambleton, A. , Pepin G., Le A., et al. 2022. “Psychiatric and Medical Comorbidities of Eating Disorders: Findings From a Rapid Review of the Literature.” Journal of Eating Disorders 10: 132. 10.1186/s40337-022-00654-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Herpertz‐Dahlmann, B. , Bonin E., and Dahmen B.. 2021. “Can You Find the Right Support for Children, Adolescents and Young Adults With Anorexia Nervosa: Access to Age‐Appropriate Care Systems in Various Healthcare Systems.” European Eating Disorders Review 29: 316–328. 10.1002/erv.2825. [DOI] [PubMed] [Google Scholar]
  24. Hudson, J. I. , Hiripi E., Pope H. G. Jr., and Kessler R. C.. 2007. “The Prevalence and Correlates of Eating Disorders in the National Comorbidity Survey Replication.” Biological Psychiatry 61, no. 3: 348–358. 10.1016/j.biopsych.2006.03.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Le Grange, D. , and Loeb K. L.. 2007. “Early Identification and Treatment of Eating Disorders: Prodrome to Syndrome.” Early Intervention in Psychiatry 1, no. 1: 27–39. 10.1111/j.1751-7893.2007.00007.x. [DOI] [PubMed] [Google Scholar]
  26. McClelland, J. , Hodsoll J., Brown A., et al. 2018. “A Pilot Evaluation of a Novel First Episode and Rapid Early Intervention Service for Eating Disorders (FREED).” European Eating Disorders Review 26, no. 2: 129–140. 10.1002/erv.2579. [DOI] [PubMed] [Google Scholar]
  27. McClelland, J. , Robinson L., Potterton R., Mountford V., and Schmidt U.. 2020. “Symptom Trajectories Into Eating Disorders: A Systematic Review of Longitudinal, Nonclinical Studies in Children/Adolescents.” European Psychiatry 63, no. 1: e60. 10.1192/j.eurpsy.2020.55oi. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mond, J. M. , Myers T. C., Crosby R. D., et al. 2008. “Screening for Eating Disorders in Primary Care: EDE‐Q Versus SCOFF.” Behaviour Research and Therapy 46, no. 5: 612–622. 10.1016/j.brat.2008.02.003. [DOI] [PubMed] [Google Scholar]
  29. NHS England . 2015. “Access and Waiting Time Standard for Children and Young People With an Eating Disorder.” https://www.england.nhs.uk/wp‐content/uploads/2015/07/cyp‐eating‐disorders‐access‐waiting‐time‐standard‐comm‐guid.pdf.
  30. NHS England . 2019. “Adult Eating Disorders: Community, Inpatient and Intensive Day Patient Care – Guidance for Commissioners and Providers.” https://www.england.nhs.uk/publication/adult‐eating‐disorders‐community‐inpatient‐and‐intensive‐day‐patient‐care‐guidance‐for‐commissioners‐and‐providers/.
  31. Nicula, M. , Pellegrini D., Grennan L., Bhatnagar N., McVey G., and Couturier J.. 2022. “Help‐Seeing Attitudes and Behaviours Among Youth With Eating Disorders: A Scoping Review.” Journal of Eating Disorders 10: 21. 10.1186/s40337-022-00543-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Potterton, R. , Austin A., Allen K., Lawrence V., and Schmidt U.. 2020. “I'm Not a Teenager, I'm 22. Why Can't I Snap Out of It?” Journal of Eating Disorders 8, no. 1: 1–14. 10.1186/s40337-020-00320-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Raffi, A. R. , Rondini M., Grandi S., and Fava G. A.. 2000. “Life Events and Prodromal Symptoms in Bulimia Nervosa.” Psychological Medicine 30, no. 3: 727–731. 10.1017/s0033291799002019. [DOI] [PubMed] [Google Scholar]
  34. Register‐Brown, K. , and Hong L. E.. 2014. “Reliability and Validity of Methods for Measuring the Duration of Untreated Psychosis: A Quantitative Review and Meta‐Analysis.” Schizophrenia Research 160, no. 1–3: 20–26. 10.1016/j,schres.2014.10.025. [DOI] [PubMed] [Google Scholar]
  35. Renwick, L. , Lyne J., Donoghue B. O., et al. 2015. “Prodromal Symptoms and Remission Following First Episode Psychosis.” Schizophrenia Research 168, no. 1–2: 30–36. 10.1016/j.schres.2015.07.001. [DOI] [PubMed] [Google Scholar]
  36. Richards, K. L. , Hyam L., Allen K. A., et al. 2022. “National Roll‐Out of Early Intervention for Eating Disorders: Process and Clinical Outcomes From First Episode Rapid Early Intervention for Eating Disorders.” Early Intervention in the Real World 17, no. 2: 202–211. 10.1111/eip.13317. [DOI] [PubMed] [Google Scholar]
  37. Schmidt, U. , Brown A., McClelland J., Glennon D., and Mountford V. A.. 2016. “Will a Comprehensive, Person‐Centered, Team‐Based Early Intervention Approach to First Episode Illness Improve Outcomes in Eating Disorders?” International Journal of Eating Disorders 49, no. 4: 374–377. 10.1002/eat.22519. [DOI] [PubMed] [Google Scholar]
  38. Schmidt, U. , Claudino A., Fernandez‐Aranda F., et al. 2025. “The Current Clinical Approach to Feeding and Eating Disorders Aims to Increase Personalization of Management.” World Psychiatry 24, no. 1: 4–31. 10.1002/wps.21263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Singh, S. P. , Cooper J. E., Fisher H. L., et al. 2005. “Determining the Chronology and Components of Psychosis Onset: The Nottingham Onset Schedule (NOS).” Schizophrenia Research 80, no. 1: 117–130. [DOI] [PubMed] [Google Scholar]
  40. Solmi, M. , Radua J., Olivola M., et al. 2022. “Age at Onset of Mental Disorders Worldwide: Large‐Scale Meta‐Analysis of 192 Epidemiological Studies.” Molecular Psychiatry 27: 281–295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Stice, E. , Desjardins C. D., Rohde P., and Shaw H.. 2021. “Sequencing of Symptom Emergence in Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorder, and Purging Disorder and Relations of Prodromal Symptoms to Future Onset of These Disorders.” Journal of Abnormal Psychology 130, no. 4: 377–387. 10.1037/abn0000666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Stice, E. , Ng J., and Shaw H.. 2010. “Risk Factors and Prodromal Eating Pathology.” Journal of Child Psychology and Psychiatry 51, no. 4: 518–525. 10.1016/j.schres.2005.04.018. [DOI] [PubMed] [Google Scholar]
  43. Stice, E. , Telch C. F., and Rizvi S. L.. 2000. “Development and Validation of the Eating Disorder Diagnostic Scale: A Brief Self‐Report Measure of Anorexia, Bulimia, and Binge‐Eating Disorder.” Psychological Assessment 12, no. 2: 123–131. 10.1037//1040-3590.12.2.123. [DOI] [PubMed] [Google Scholar]
  44. Swanson, S. A. , Crow S. J., Le Grange D., Swendsen J., and Merikangas K. R.. 2011. “Prevalence and Correlates of Eating Disorders in Adolescents. Results From the National Comorbidity Survey Replication Adolescent Supplement.” Archives of General Psychiatry 68, no. 7: 714–723. 10.1001/archgenpsychiatry.2011.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Treasure, J. , Oyeleye O., Bonin E.‐M., Zipfel S., and Fernandez‐Aranda F.. 2021. “Optimising Care Pathways for Adult Anorexia Nervosa. What Is the Evidence to Guide the Provision of High‐Quality, Cost‐Effective Services?” European Eating Disorders Review 29: 306–315. 10.1002/erv.2821. [DOI] [PubMed] [Google Scholar]
  46. Treasure, J. , Stein D., and Maguire S.. 2015. “Has the Time Come for a Staging Model to Map the Course of Eating Disorders From High Risk to Severe Enduring Illness? An Examination of the Evidence.” Early Intervention in Psychiatry 9, no. 3: 173–184. 10.1111/eip.12170. [DOI] [PubMed] [Google Scholar]
  47. Valmaggia, L. R. , Byrne M., Day F., et al. 2015. “Duration of Untreated Psychosis and Need for Admission in Patients Who Engage With Mental Health Services in the Prodromal Phase.” British Journal of Psychiatry 207, no. 2: 130–134. 10.1192/bjp.bp.114.150623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Van Meter, A. R. , Burke C., Youngstrom E. A., Faedda G. L., and Correll C. U.. 2016. “The Bipolar Prodrome: Meta‐Analysis of Symptom Prevalence Prior to Initial or Recurrent Mood Episodes.” Journal of the American Academy of Child & Adolescent Psychiatry 55, no. 7: 543–555. 10.1016/j.jaac.2016.04.017. [DOI] [PubMed] [Google Scholar]
  49. Weigel, A. , Rossi M., Wendt H., et al. 2014. “Duration of Untreated Illness and Predictors of Late Treatment Initiation in Anorexia Nervosa.” Journal of Public Health 22, no. 6: 519–527. 10.1007/s10389-014-0642-7. [DOI] [Google Scholar]
  50. Woodberry, K. A. , Shapiro D. I., Bryant C., and Seidman L. J.. 2016. “Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians.” Harvard Review of Psychiatry 24, no. 2: 87–103. 10.1097/HRP.0000000000000109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Yamamiya, Y. , Desjardins C. D., and Stice E.. 2023. “Sequencing of Symptom Emergence in Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorder, and Purging Disorder in Adolescent Girls and Relations of Prodromal Symptoms to Future Onset of These Eating Disorders.” Psychological Medicine 53, no. 10: 4657–4665. 10.1017/S0033291722001568. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data S1: eip70164‐sup‐0001‐Supinfo.docx.

EIP-20-0-s001.docx (15.1KB, docx)

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Articles from Early Intervention in Psychiatry are provided here courtesy of Wiley

RESOURCES